Ca19-9, The Clinical Significance In The Diagnosis Of Ovarian Mature Cystic Teratoma

Background:Mature cystic teratoma of the ovary is the most common gynecological cancer, ovarian cancer incidence accounted for 10% to 20%, accounting for 85% of germ cells to 97%, accounting for 95% of teratomas. Can occur at any age, mostly 20 to 40 years old. Mostly unilateral, bilateral,10%-17%. Malignant transformation rate of 1% to 3% (more common in postmenopausal women). Are only a few studies of tumor markers in the diagnosis of mature teratoma in the role. CA19-9 antigen for the gastrointestinal tract, but as a tumor marker widely used in gynecology. Studies on serum levels of CA19-9 in mature cystic teratoma in the diagnosis of only a few articles so far at home and abroad are still reported, these reports show that patients with mature cystic teratoma CA19-9 is the only elevated tumor marker, increased 45% to 59%. In recent years, domestic-related translations and also that of the CA19-9 diagnosis of mature cystic teratoma is an important indicator, its value increased with tumor size, one associated with bilateral certain. CA19-9 may be the diagnosis of ovarian mature cystic teratoma is an important tumor marker.Objective:To analyze 83 cases of mature cystic teratoma in patients with serum levels of CA19-9 values, assess its relationship with tumor size and patient age at onset of unilateral and bilateral relations. Methods:First Hospital of Shanxi Medical University, gynecological January 2007-May 2009 hospitalized patients with mature cystic teratoma complete medical records were reviewed retrospectively 83 cases. By CA19-9 values were divided into two groups, namely, elevated CA19-9 values (groupⅠ) and CA19-9 value of the normal group (groupⅡ), two groups of patients between the age of onset, tumor size, single and double side, and the increased rate of tumor markers were compared. All data were analyzed using SPSS16.0 package, with±S said measurement data between the two groups using t test and rank sum test, P<0.05 was significant.Results:(1) The average age of 37.1±12.1 years (range 14 to 69 years old), groupⅠaverage age of 35.21±13.40 years (range 14-69 years), groupⅡaverage age of 39.56±10.23years (range 19-57 years). (2) the average tumor diameter was 8.2±3.2cm (range 3-22cm), groupⅠaverage diameter of 9.27±3.47cm (range 5-22cm), diameter≥8cm accounted for 69.05%, groupⅡaverage diameter of 7.323±2.77cm (range 3-10cm)), diameter≥8cm accounted for 39.02%. (3) unilateral tumor incidence was 84.33%, unilateral rate of 84.34% in groupⅠand groupⅡunilateral rate of 87.80%. (4) the average level of serum CA19-9 was 52.01±55.31U/L (range 1.04-245.25U/L, normal<30U/L), increased rate of 50.60%; mean serum CA125 level was 16.90±23.31U/L (range 2.96-202.11U/L, normal<35U/ml), increased rate of 5.21%, higher rate of 4.76% in groupⅠand groupⅡincreased rate of 7.32%; mean serum CEA level was 1.36±0.87Ug/L (range 0.1-20.42 Ug/L, normal<15 Ug/L), increased rate of 2.41%, higher rate of 4.76% in groupⅠand groupⅡincreased rate of 0%; mean serum AFP level was 2.43±1.62 Ug/L (range 0.4-22.06 Ug/L, normal<20 Ug/L), increased rate of 1.20%. Higher rate of 2.34% in groupⅠand groupⅡincreased rate of 0%.Conclusions:(1) elevated levels of serum CA19-9 were larger tumor diameter. (2)tumors was unilateral, and the level of serum CA19-9 and other tumor markers had no relationship. (3)ovarian mature cystic teratoma occurs mainly in women of childbearing age. (4) elevated levels of serum CA19-9, other tumor markers may also be increased.